IL132520A0 - A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor - Google Patents

A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor

Info

Publication number
IL132520A0
IL132520A0 IL13252098A IL13252098A IL132520A0 IL 132520 A0 IL132520 A0 IL 132520A0 IL 13252098 A IL13252098 A IL 13252098A IL 13252098 A IL13252098 A IL 13252098A IL 132520 A0 IL132520 A0 IL 132520A0
Authority
IL
Israel
Prior art keywords
inhibitor
pharmaceutical composition
protein kinase
skin disorders
treating skin
Prior art date
Application number
IL13252098A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL132520A0 publication Critical patent/IL132520A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
IL13252098A 1997-04-30 1998-04-21 A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor IL132520A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4443197P 1997-04-30 1997-04-30
PCT/US1998/007808 WO1998048795A1 (en) 1997-04-30 1998-04-21 Therapeutic treatment for skin disorders

Publications (1)

Publication Number Publication Date
IL132520A0 true IL132520A0 (en) 2001-03-19

Family

ID=21932346

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13252098A IL132520A0 (en) 1997-04-30 1998-04-21 A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor

Country Status (16)

Country Link
US (1) US6093740A (de)
EP (1) EP0903145A3 (de)
JP (1) JP2002501501A (de)
KR (1) KR20010020381A (de)
CN (1) CN1259866A (de)
AU (1) AU7131898A (de)
BR (1) BR9809343A (de)
CA (1) CA2289257A1 (de)
EA (1) EA199900987A1 (de)
HU (1) HUP0002836A2 (de)
ID (1) ID23528A (de)
IL (1) IL132520A0 (de)
NO (1) NO995231L (de)
PL (1) PL336760A1 (de)
TR (1) TR199902682T2 (de)
WO (1) WO1998048795A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037502A2 (en) * 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
CA2395136A1 (en) * 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
JP3429297B1 (ja) 2002-02-20 2003-07-22 株式会社ノエビア 皮膚外用剤
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
TWI428143B (zh) 2006-01-18 2014-03-01 Gen Hospital Corp 增加淋巴功能之方法
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
CN101380317B (zh) * 2007-09-07 2010-12-08 英属开曼群岛商安盛开发药物股份有限公司 减缓搔痒症的药学组合物
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
CN110300584A (zh) * 2016-12-19 2019-10-01 克罗马德姆公司 治疗色素沉着过度病症的方法
CA3255435A1 (en) 2022-05-20 2023-11-23 Dermbiont, Inc. Compositions and formulations allowing the use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
NO308798B1 (no) * 1993-12-07 2000-10-30 Lilly Co Eli Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
DK0657411T3 (da) * 1993-12-07 1999-11-15 Lilly Co Eli Forbedret syntese af bisindolylmaleimider
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
YU49315B (sh) * 1995-11-20 2005-06-10 Elli Lilly And Company Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
EP0915698A4 (de) * 1996-05-01 1999-08-11 Lilly Co Eli Behandlungsverfahren für vegf-anverwandte erkrankungen
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту

Also Published As

Publication number Publication date
WO1998048795A1 (en) 1998-11-05
TR199902682T2 (xx) 2000-05-22
NO995231D0 (no) 1999-10-26
US6093740A (en) 2000-07-25
KR20010020381A (ko) 2001-03-15
JP2002501501A (ja) 2002-01-15
PL336760A1 (en) 2000-07-17
NO995231L (no) 1999-12-27
EA199900987A1 (ru) 2000-08-28
BR9809343A (pt) 2000-07-04
CN1259866A (zh) 2000-07-12
EP0903145A2 (de) 1999-03-24
HUP0002836A2 (hu) 2001-02-28
ID23528A (id) 2000-04-27
CA2289257A1 (en) 1998-11-05
AU7131898A (en) 1998-11-24
EP0903145A3 (de) 2001-02-07

Similar Documents

Publication Publication Date Title
EG23871A (en) Protein kinase c inhibitor
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HUP0002183A3 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
CY2561B1 (en) Protein kinase C inhibitors
HUP9802086A3 (en) Pharmaceutical composition for piperidinoalkanol compounds
IL130027A (en) Rosiglitazone - glyburide synergistic combinations for treatment of diabetes
IL132520A0 (en) A pharmaceutical composition for treating skin disorders containing a protein kinase c inhibitor
IL118590A (en) Pharmaceutical composition for minimizing bone loss
ZA964373B (en) A pharmaceutical composition for treating lukemia
HUP9903684A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating depression
EP1012150A4 (de) Heteroarylcarboxamid-verbindungen die gegen durch protein-tyrosin-kinase verursachte krankheiten wirksam sind
HUP0003679A3 (en) Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases
HU9800396D0 (en) Pharmaceutical composition for treating dementia
HUP9904173A3 (en) Pharmaceutical composition for treating viral diseases
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
ZA949611B (en) Protein kinase C inhibitors
EP1007041A4 (de) Zusammensetzung zur behandlung von schmerzen
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia
AU2003200309A1 (en) Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases
HUP0003236A3 (en) Medicinal compositions for treating immunodeficiency diseases
IL116680A0 (en) Pharmaceutical composition for the treatment of depression
AUPO882597A0 (en) Pharmaceutical composition for the treatment of skin disorders
IL121488A0 (en) A pharmaceutical composition for the treatment of multiple sclerosis
HUP9702369A3 (en) Pharmaceutical composition of natural active components for treating kinetose
IL122092A0 (en) Protein kinase C inhibitors